ImmunoGen Management

Management criteria checks 2/4

ImmunoGen's CEO is Mark Enyedy, appointed in May 2016, has a tenure of 6.5 years. total yearly compensation is $7.44M, comprised of 9.9% salary and 90.1% bonuses, including company stock and options. directly owns 0.2% of the company’s shares, worth €2.10M. The average tenure of the management team and the board of directors is 2.4 years and 10.8 years respectively.

Key information

Mark Enyedy

Chief executive officer

US$7.4m

Total compensation

CEO salary percentage9.9%
CEO tenure6.5yrs
CEO ownership0.2%
Management average tenure2.4yrs
Board average tenure10.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Mark Enyedy's remuneration changed compared to ImmunoGen's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2022n/an/a

-US$201m

Jun 30 2022n/an/a

-US$161m

Mar 31 2022n/an/a

-US$129m

Dec 31 2021US$7mUS$735k

-US$139m

Sep 30 2021n/an/a

-US$71m

Jun 30 2021n/an/a

-US$56m

Mar 31 2021n/an/a

-US$49m

Dec 31 2020US$5mUS$714k

-US$44m

Sep 30 2020n/an/a

-US$71m

Jun 30 2020n/an/a

-US$70m

Mar 31 2020n/an/a

-US$89m

Dec 31 2019US$4mUS$710k

-US$104m

Sep 30 2019n/an/a

-US$151m

Jun 30 2019n/an/a

-US$176m

Mar 31 2019n/an/a

-US$174m

Dec 31 2018US$9mUS$687k

-US$169m

Sep 30 2018n/an/a

-US$140m

Jun 30 2018n/an/a

-US$150m

Mar 31 2018n/an/a

-US$117m

Dec 31 2017US$3mUS$670k

-US$96m

Sep 30 2017n/an/a

-US$117m

Jun 30 2017n/an/a

-US$105m

Mar 31 2017n/an/a

-US$142m

Dec 31 2016US$569kUS$325k

-US$157m

Compensation vs Market: Mark's total compensation ($USD7.44M) is above average for companies of similar size in the German market ($USD1.19M).

Compensation vs Earnings: Mark's compensation has increased whilst the company is unprofitable.


CEO

Mark Enyedy (58 yo)

6.5yrs

Tenure

US$7,440,507

Compensation

Mr. Mark Joseph Enyedy is Non-Executive Director at Ergomed plc since June 10, 2021. He has been the Chief Executive Officer and President at ImmunoGen, Inc. since May 16, 2016 and served as its Interim Pr...


Leadership Team

NamePositionTenureCompensationOwnership
Mark Enyedy
President6.5yrsUS$7.44m0.20%
$ 2.1m
Susan Altschuller
Senior VP & CFO2.3yrsUS$1.53m0%
$ 0
Anna Berkenblit
Senior VP & Chief Medical Officer7.6yrsUS$2.51m0.050%
$ 531.7k
Stacy Coen
Senior VP & Chief Business Officer2.4yrsUS$1.61m0.0032%
$ 34.6k
Renee Lentini
VP of Finance & Principal Accounting Officer1.8yrsno data0.0083%
$ 88.3k
Courtney O'Konek
Senior Director of Corporate Communications & Investor Relationsno datano datano data
Joseph Kenny
VP, Acting General Counselno datano datano data
Audrey Bergan
Senior VP & Chief HR Officer4.3yrsno datano data
Theresa Wingrove
Senior Vice President of Regulatory Affairs & Qualityno dataUS$1.27m0.037%
$ 396.5k
Mary Huizinga
Senior VP & Head of Medical Affairsless than a yearno datano data

2.4yrs

Average Tenure

51yo

Average Age

Experienced Management: IMU's management team is considered experienced (2.4 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Mark Enyedy
President6.5yrsUS$7.44m0.20%
$ 2.1m
Stephen McCluski
Independent Chairman15.6yrsUS$406.07k0%
$ 0
Dean Mitchell
Independent Director10.8yrsUS$365.07k0.042%
$ 448.5k
Kristine Peterson
Independent Director10.8yrsUS$375.07k0%
$ 0
Helen Thackray
Independent Director1.2yrsUS$374.79k0%
$ 0
Richard Wallace
Independent Director15yrsUS$368.07k0%
$ 0
Stuart Arbuckle
Independent Director4.8yrsUS$358.07k0%
$ 0
Mark A. Goldberg
Independent Director11yrsUS$365.07k0.024%
$ 259.4k
Tracey McCain
Independent Directorless than a yearUS$351.30k0%
$ 0

10.8yrs

Average Tenure

63yo

Average Age

Experienced Board: IMU's board of directors are seasoned and experienced ( 10.8 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.